ArriVent BioPharma (AVBP) Liabilities and Shareholders Equity (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $349.3 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 62.09% year-over-year to $349.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 17.08% YoY), and the FY2025 full-year result was $333.2 million, up 21.18% from the prior year.
• Liabilities and Shareholders Equity grew to $349.3 million in Q1 2026, from $333.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $349.3 million in Q1 2026 to a low of $163.1 million in Q4 2023.
• A 4-year average of $286.1 million and a median of $300.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 68.57% in 2024 and plunged 34.27% in 2025, its largest moves.
• Tracing AVBP's Liabilities and Shareholders Equity over 4 years: stood at $163.1 million in 2023, then soared by 68.57% to $274.9 million in 2024, then advanced by 21.18% to $333.2 million in 2025, then rose by 4.84% to $349.3 million in 2026.
• Business Quant data shows AVBP's Liabilities and Shareholders Equity at $349.3 million in Q1 2026, $333.2 million in Q4 2025, and $326.6 million in Q3 2025.